Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 9/2013

01.09.2013 | Original Paper

Patients with advanced cancer and their usage of complementary and alternative medicine

verfasst von: Magda Paul, B. Davey, B. Senf, C. Stoll, K. Münstedt, R. Mücke, Oliver Micke, F. J. Prott, J. Buentzel, Jutta Hübner

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 9/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

A total of 40 % of cancer patients use complementary and alternative medicine (CAM), and patients with advanced cancer use CAM more often than others. The aim of our study was to gather data on CAM use and reasons to use CAM of patients with advanced cancer being admitted for residential palliative care and their relatives.

Methods

Structured interviews were carried out with 25 patients and 25 relatives of those patients, respectively, of a German comprehensive cancer center based on a standardized questionnaire of the working group Prevention and Integrative Oncology of the German Cancer Society.

Results

Median age of patients was 64.5 years (relatives: 53.5); 15 patients were male and 10 were female (relatives: 7 and 18). In total, 40 % of all patients used some CAM method at the time of the study, supplements and prayer being the most frequent method. Main reasons for using CAM were to sustain one’s own strength (52 % for patients and 72 % for relatives) and to be able to do something by oneself (36 and 40 %). Sources of information were television/radio (48 and 28 %) and family/friends (40 and 48 %). Relatives also use the Internet (40 %).

Conclusions

Also for patients in palliative care and their relatives, CAM is important. Reasons for using CAM are similar for patients with less advanced cancer. As most patients do not discuss using CAM with their physician, side effects and interactions of biologically based treatments may be dangerous. The desire of patients to act autonomously should be encouraged. Yet, physicians should ensure safe administration of complementary methods by including CAM in their communication with the patient and the family.
Literatur
Zurück zum Zitat Brauer JA, El Sehamy A, Metz JM, Mao JJ (2010) Complementary and alternative medicine and supportive care at leading cancer centers: a systematic analysis of websites. J Altern Complement Med 16(2):183–186PubMedCrossRef Brauer JA, El Sehamy A, Metz JM, Mao JJ (2010) Complementary and alternative medicine and supportive care at leading cancer centers: a systematic analysis of websites. J Altern Complement Med 16(2):183–186PubMedCrossRef
Zurück zum Zitat Broom A, Tovey P (2008) The role of the Internet in cancer patients’ engagement with complementary and alternative treatments. Health (London) 12(2):139–155CrossRef Broom A, Tovey P (2008) The role of the Internet in cancer patients’ engagement with complementary and alternative treatments. Health (London) 12(2):139–155CrossRef
Zurück zum Zitat Büntzel J, Glatzel M, Bruns F, Kisters K (2003) Use of complementary/alternative therapy methods by patients with breast cancer. Forsch Komplementarmed Klass Naturheilkd 10(6):304–308PubMedCrossRef Büntzel J, Glatzel M, Bruns F, Kisters K (2003) Use of complementary/alternative therapy methods by patients with breast cancer. Forsch Komplementarmed Klass Naturheilkd 10(6):304–308PubMedCrossRef
Zurück zum Zitat Eng J, Ramsum D, Verhoef M, Guns E, Davison J, Gallagher R (2003) A population-based survey of complementary and alternative medicine use in men recently diagnosed with prostate cancer. Integr Cancer Ther 2:212–216PubMedCrossRef Eng J, Ramsum D, Verhoef M, Guns E, Davison J, Gallagher R (2003) A population-based survey of complementary and alternative medicine use in men recently diagnosed with prostate cancer. Integr Cancer Ther 2:212–216PubMedCrossRef
Zurück zum Zitat Eschiti VS (2007) Lesson from comparison of CAM use by women with female-specific cancers to others: it‘s time to focus on interaction risks with CAM therapies. Integr Cancer Ther 6(4):313–344PubMedCrossRef Eschiti VS (2007) Lesson from comparison of CAM use by women with female-specific cancers to others: it‘s time to focus on interaction risks with CAM therapies. Integr Cancer Ther 6(4):313–344PubMedCrossRef
Zurück zum Zitat Hlubocky FJ, Ratain MJ, Wen M, Daugherty CK (2007) Complementary and alternative medicine among advanced cancer patients enrolled on phase I trials: a study of prognosis, quality of life, and preferences for decision making. J Clin Oncol 25(5):548–554PubMedCrossRef Hlubocky FJ, Ratain MJ, Wen M, Daugherty CK (2007) Complementary and alternative medicine among advanced cancer patients enrolled on phase I trials: a study of prognosis, quality of life, and preferences for decision making. J Clin Oncol 25(5):548–554PubMedCrossRef
Zurück zum Zitat Horneber M, Bueschel G, Dennert G, Less D, Ritter E, Zwahlen M (2012) How many cancer patients use complementary and alternative medicine: a systematic review and metaanalysis. Integr Cancer Ther 11(3):187–203PubMedCrossRef Horneber M, Bueschel G, Dennert G, Less D, Ritter E, Zwahlen M (2012) How many cancer patients use complementary and alternative medicine: a systematic review and metaanalysis. Integr Cancer Ther 11(3):187–203PubMedCrossRef
Zurück zum Zitat Klafke N (2012) Prevalence and predictors of complementary and alternative medicine (CAM) use by men in Australian cancer outpatient services. Ann Oncol 23:1571–1578PubMedCrossRef Klafke N (2012) Prevalence and predictors of complementary and alternative medicine (CAM) use by men in Australian cancer outpatient services. Ann Oncol 23:1571–1578PubMedCrossRef
Zurück zum Zitat Matthews SC, Camacho A, Mills PJ, Dimsdale JE (2003) The internet for medical information about cancer: help or hindrance? Psychosomatics 44(2):100–103PubMedCrossRef Matthews SC, Camacho A, Mills PJ, Dimsdale JE (2003) The internet for medical information about cancer: help or hindrance? Psychosomatics 44(2):100–103PubMedCrossRef
Zurück zum Zitat Micke O, Bruns F, Glatzel M, Schönekaes K, Micke P, Mücke R, Büntzel J (2009) Predictive factors for the use of complementary and alternative medicine (CAM) in radiation oncology. Eur J Integr Med 1:22–30 Micke O, Bruns F, Glatzel M, Schönekaes K, Micke P, Mücke R, Büntzel J (2009) Predictive factors for the use of complementary and alternative medicine (CAM) in radiation oncology. Eur J Integr Med 1:22–30
Zurück zum Zitat Molassiotis A, Fernadez-Ortega P, Pud D, Ozden G, Scott JA, Panteli V, Margulies A, Browall M, Magri M, Selvekerova S, Madsen E, Milovics L, Bruyns I, Gudmundsdottir G, Hummerston S, Ahmad AM, Platin N, Kearney N, Patiraki E (2005) Use of complementary and alternative medicine in cancer patients: a European survey. Ann Oncol 16:655–663PubMedCrossRef Molassiotis A, Fernadez-Ortega P, Pud D, Ozden G, Scott JA, Panteli V, Margulies A, Browall M, Magri M, Selvekerova S, Madsen E, Milovics L, Bruyns I, Gudmundsdottir G, Hummerston S, Ahmad AM, Platin N, Kearney N, Patiraki E (2005) Use of complementary and alternative medicine in cancer patients: a European survey. Ann Oncol 16:655–663PubMedCrossRef
Zurück zum Zitat Richardson MA (2000) Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 18(13):2505–2514PubMed Richardson MA (2000) Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 18(13):2505–2514PubMed
Zurück zum Zitat Sollner W (1997) Attitude toward alternative therapy, compliance with standard treatment, and need for emotional support in patients with melanoma. Arch Dermatol 133(3):316–321PubMedCrossRef Sollner W (1997) Attitude toward alternative therapy, compliance with standard treatment, and need for emotional support in patients with melanoma. Arch Dermatol 133(3):316–321PubMedCrossRef
Zurück zum Zitat Sollner W, Maislinger S, DeVries A, Steixner E, Rumpold G, Lukas P (2000) Use of complementary and alternative medicine by cancer patients is not associated with perceived distress or poor compliance with standard treatment but with active coping behavior: a survey. Cancer 89(4):873–880PubMedCrossRef Sollner W, Maislinger S, DeVries A, Steixner E, Rumpold G, Lukas P (2000) Use of complementary and alternative medicine by cancer patients is not associated with perceived distress or poor compliance with standard treatment but with active coping behavior: a survey. Cancer 89(4):873–880PubMedCrossRef
Zurück zum Zitat Yates JS et al (2005) Prevalence of complementary and alternative medicine use in cancer patients during treatment. Support Care Cancer 13(10):806–811PubMedCrossRef Yates JS et al (2005) Prevalence of complementary and alternative medicine use in cancer patients during treatment. Support Care Cancer 13(10):806–811PubMedCrossRef
Zurück zum Zitat Zeller T, Muenstedt K, Stoll C, Schweder J, Senf B, Ruckhaeberle E et al (2013) Potential interactions of complementary and alternative medicine with cancer therapy in outpatients with gynecological cancer in a comprehensive cancer center. J Cancer Res Clin Oncol 139:357–365PubMedCrossRef Zeller T, Muenstedt K, Stoll C, Schweder J, Senf B, Ruckhaeberle E et al (2013) Potential interactions of complementary and alternative medicine with cancer therapy in outpatients with gynecological cancer in a comprehensive cancer center. J Cancer Res Clin Oncol 139:357–365PubMedCrossRef
Metadaten
Titel
Patients with advanced cancer and their usage of complementary and alternative medicine
verfasst von
Magda Paul
B. Davey
B. Senf
C. Stoll
K. Münstedt
R. Mücke
Oliver Micke
F. J. Prott
J. Buentzel
Jutta Hübner
Publikationsdatum
01.09.2013
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 9/2013
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-013-1460-y

Weitere Artikel der Ausgabe 9/2013

Journal of Cancer Research and Clinical Oncology 9/2013 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.